AdAlta

AdAlta Ltd (1AD) is an Australian-based drug development company headquartered in Melbourne. The Company is using its proprietary technology platform to generate a promising new class of single domain antibody protein therapeutics, known as i-bodies, that have the potential to treat some of today's most challenging medical conditions. The technology mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein.

Contact Details

Unit 15 , 2 Park Dr BUNDOORA VIC 3083

03 9479 5159

enquiries@adalta.com.au

www.adalta.com.au

Lists and Charts

Share price

AdAlta
Closing price for the last 90 trading days

View ASX Chart

Total Shareholder Return as at 02/12/24

Rank	Company	1 Yr	5 Yr
1155^th	Zuleika Gold	-23.29%	-4.38%
1156^th	Weebit Nano	-23.33%	45.19%
1157^th	AdAlta	-23.35%	-30.08%
1158^th	Enero Group	-23.46%	-4.56%
1159^th	Minbos Resources	-23.51%	23.91%

View Full List

1767 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Company Share Transactions

Company Activity

	NEW ROLE: Robert Peach, Non-Executive Director	03 Jul 2024
	NEW ROLE: David Fuller, Non-Executive Director	03 Nov 2020
	NEW ROLE: Liddy McCall, Non-Executive Director	03 Nov 2020
	NEW ROLE: Paul MacLeman, Executive Chairman	03 Nov 2020
	NEW ROLE: James Williams, Alternate Director	03 Nov 2020
	NEW ROLE: Timothy Oldham, Managing Director, Chief Executive Officer	03 Nov 2020
	NEW ROLE: Colin Boyan, Non-Executive Director	03 Nov 2020
	NEW ROLE: Cameron Jones, Chief Financial Officer, Company Secretary	03 Nov 2020

Related Information

Access to our data for AdAlta is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

AdAlta is included in 1 list - Public Companies - non WA.

For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

Subscribe today